CL2004001507A1 - Compuestos derivados de espirobenzobenzazepinas sustituidos, inhibidores de receptores de vasopresina; composicion farmaceutica; utiles en el tratamiento de hipertension, disfuncion cardiaca, insuficiencia renal, entre otras. - Google Patents

Compuestos derivados de espirobenzobenzazepinas sustituidos, inhibidores de receptores de vasopresina; composicion farmaceutica; utiles en el tratamiento de hipertension, disfuncion cardiaca, insuficiencia renal, entre otras.

Info

Publication number
CL2004001507A1
CL2004001507A1 CL200401507A CL2004001507A CL2004001507A1 CL 2004001507 A1 CL2004001507 A1 CL 2004001507A1 CL 200401507 A CL200401507 A CL 200401507A CL 2004001507 A CL2004001507 A CL 2004001507A CL 2004001507 A1 CL2004001507 A1 CL 2004001507A1
Authority
CL
Chile
Prior art keywords
vasopresine
espirobenzobenzazepinas
hypertension
inhibitors
receiver
Prior art date
Application number
CL200401507A
Other languages
English (en)
Spanish (es)
Inventor
Mona Rybczynski Philip J Patel
Original Assignee
Ortho Mcneil Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Mcneil Pharm Inc filed Critical Ortho Mcneil Pharm Inc
Publication of CL2004001507A1 publication Critical patent/CL2004001507A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/49Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups
    • C07C205/57Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups having nitro groups and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D223/00Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/32Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems containing carbocyclic rings other than six-membered

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CL200401507A 2003-06-17 2004-06-17 Compuestos derivados de espirobenzobenzazepinas sustituidos, inhibidores de receptores de vasopresina; composicion farmaceutica; utiles en el tratamiento de hipertension, disfuncion cardiaca, insuficiencia renal, entre otras. CL2004001507A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US47937803P 2003-06-17 2003-06-17

Publications (1)

Publication Number Publication Date
CL2004001507A1 true CL2004001507A1 (es) 2005-05-27

Family

ID=34465052

Family Applications (1)

Application Number Title Priority Date Filing Date
CL200401507A CL2004001507A1 (es) 2003-06-17 2004-06-17 Compuestos derivados de espirobenzobenzazepinas sustituidos, inhibidores de receptores de vasopresina; composicion farmaceutica; utiles en el tratamiento de hipertension, disfuncion cardiaca, insuficiencia renal, entre otras.

Country Status (30)

Country Link
US (2) US20040266752A1 (OSRAM)
EP (1) EP1633719B1 (OSRAM)
JP (1) JP5252614B2 (OSRAM)
KR (1) KR101086246B1 (OSRAM)
CN (1) CN100467454C (OSRAM)
AR (1) AR044782A1 (OSRAM)
AT (1) ATE444953T1 (OSRAM)
AU (1) AU2004281257C1 (OSRAM)
BR (1) BRPI0411598A (OSRAM)
CA (1) CA2529649C (OSRAM)
CL (1) CL2004001507A1 (OSRAM)
CR (1) CR8168A (OSRAM)
CY (1) CY1109585T1 (OSRAM)
DE (1) DE602004023501D1 (OSRAM)
DK (1) DK1633719T3 (OSRAM)
EA (1) EA011089B1 (OSRAM)
ES (1) ES2332724T3 (OSRAM)
HR (2) HRP20051006A2 (OSRAM)
IL (1) IL172630A (OSRAM)
ME (1) ME00320B (OSRAM)
NO (1) NO20060247L (OSRAM)
NZ (1) NZ544180A (OSRAM)
PL (1) PL1633719T3 (OSRAM)
PT (1) PT1633719E (OSRAM)
RS (1) RS20050930A (OSRAM)
SI (1) SI1633719T1 (OSRAM)
TW (1) TWI354555B (OSRAM)
UA (1) UA82236C2 (OSRAM)
WO (1) WO2005037795A2 (OSRAM)
ZA (1) ZA200600430B (OSRAM)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20051005A2 (en) * 2003-06-17 2006-09-30 Janssen Pharmaceutica N.V. Process for the preparation of nonpeptide substituted spirobenzoazepine derivatives
CA2637838A1 (en) * 2006-01-20 2007-07-26 Janssen Pharmaceutica N.V. Novel solid forms of (4r)-1-¬4-(2-chloro-5-fluorobenzoyl)amino-3-methoxybenzoyl|-1,2,3,5-tetrahydro-spiro¬4h-1-benzazepine-4,1'-¬2|cyclopentene|-3'-carboxylic acid
CN101541807A (zh) 2006-09-22 2009-09-23 詹森药业有限公司 用作血管升压素拮抗剂的螺环苯并氮杂
WO2008036755A1 (en) 2006-09-22 2008-03-27 Janssen Pharmaceutica N.V. Spiro benzazepines used as vasopressin antagonists
AR066834A1 (es) * 2007-06-06 2009-09-16 Janssen Pharmaceutica Nv Espirobenzoazepanos como antagonistas de vasopresina, composiciones farmaceuticas que los contienen, proceso de preparacion y usos para el tratamiento de afecciones cardiacas, renales y del sistema nervioso central.
JP2011503085A (ja) * 2007-11-07 2011-01-27 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ アンギオテンシン変換酵素阻害剤及びバソプレッシン受容体拮抗薬を含む複合治療
WO2014062888A1 (en) 2012-10-18 2014-04-24 University Of South Florida Compositions and methods for treating stroke
JP5968466B2 (ja) 2012-12-26 2016-08-10 株式会社三和化学研究所 新規ベンゾアゼピン誘導体及びその医薬用途
KR20230152111A (ko) * 2021-03-05 2023-11-02 상하이 제민케어 파마슈티칼 컴퍼니 리미티드 신규 벤자제핀 융합 고리 유도체

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4617302A (en) * 1984-10-15 1986-10-14 Eli Lilly And Company Inotropic agents
WO1991005549A1 (en) 1989-10-20 1991-05-02 Otsuka Pharmaceutical Co., Ltd. Benzoheterocyclic compounds
US5258510A (en) * 1989-10-20 1993-11-02 Otsuka Pharma Co Ltd Benzoheterocyclic compounds
US5985869A (en) * 1989-10-20 1999-11-16 Otsuka Pharmaceutical Company, Limited Benzoheterocyclic compounds
US5686624A (en) * 1992-01-30 1997-11-11 Sanofi 1-benzenesulfonyl-1,3-dihydro-indol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present
FR2708605A1 (fr) * 1993-07-30 1995-02-10 Sanofi Sa Dérivés du N-sulfonylindol-2-one, leur préparation, les compositions pharmaceutiques en contenant.
US5663431A (en) * 1992-01-30 1997-09-02 Sanofi 1-benzenesulfonyl-1,3-dihydro-indol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present
US5849780A (en) * 1992-01-30 1998-12-15 Sanofi 1-benzenesulfonyl-1-1,3-dihydroindol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present
WO1994007496A1 (en) * 1992-10-07 1994-04-14 Merck & Co., Inc. Tocolytic oxytocin receptor antagonists
US5512563A (en) 1993-07-29 1996-04-30 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
US5464788A (en) * 1994-03-24 1995-11-07 Merck & Co., Inc. Tocolytic oxytocin receptor antagonists
ATE189121T1 (de) * 1994-04-22 2000-02-15 Pentech Pharmaceuticals Inc Sublinguale dosierungsformen enthaltend apomorphin zur verwendung bei der behandlung von erektiler dysfunktion
US5753648A (en) * 1995-01-17 1998-05-19 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
JP3282494B2 (ja) * 1995-05-16 2002-05-13 富士ゼロックス株式会社 画像定着装置
US5753715A (en) * 1995-06-02 1998-05-19 Ortho Pharmaceutical Corporation 2-disubstituted cyclohexenyl and cyclohexyl antimicrobial agents
US5726723A (en) * 1996-01-31 1998-03-10 Technology Research International Corporation Sub-twisted nematic liquid crystal display
AUPP150098A0 (en) 1998-01-27 1998-02-19 Fujisawa Pharmaceutical Co., Ltd. Benzamide derivatives
ATE305454T1 (de) * 2000-07-05 2005-10-15 Ortho Mcneil Pharm Inc Nichtpeptidische substituierte spirobenzoazepine als vasopressin antagonisten
HRP20051005A2 (en) 2003-06-17 2006-09-30 Janssen Pharmaceutica N.V. Process for the preparation of nonpeptide substituted spirobenzoazepine derivatives

Also Published As

Publication number Publication date
NO20060247L (no) 2006-03-13
AU2004281257B2 (en) 2010-02-04
CN100467454C (zh) 2009-03-11
US20040266752A1 (en) 2004-12-30
EP1633719A2 (en) 2006-03-15
UA82236C2 (en) 2008-03-25
US20070179128A1 (en) 2007-08-02
KR101086246B1 (ko) 2011-11-23
TWI354555B (en) 2011-12-21
EA200501831A1 (ru) 2006-06-30
MEP49108A (en) 2011-02-10
JP2007521272A (ja) 2007-08-02
CY1109585T1 (el) 2014-08-13
KR20060023157A (ko) 2006-03-13
ES2332724T3 (es) 2010-02-11
HRP20090606T1 (hr) 2010-01-31
CN1835925A (zh) 2006-09-20
WO2005037795A3 (en) 2005-07-28
HRP20051006A2 (en) 2006-05-31
BRPI0411598A (pt) 2006-08-29
CA2529649C (en) 2012-01-31
WO2005037795A2 (en) 2005-04-28
ME00320B (me) 2011-05-10
SI1633719T1 (sl) 2010-01-29
EA011089B1 (ru) 2008-12-30
DK1633719T3 (da) 2010-01-04
AR044782A1 (es) 2005-10-05
US7687494B2 (en) 2010-03-30
NZ544180A (en) 2009-01-31
DE602004023501D1 (de) 2009-11-19
EP1633719B1 (en) 2009-10-07
ZA200600430B (en) 2009-08-26
CA2529649A1 (en) 2005-04-28
TW200515911A (en) 2005-05-16
AU2004281257A1 (en) 2005-04-28
CR8168A (es) 2008-09-10
PT1633719E (pt) 2009-11-11
JP5252614B2 (ja) 2013-07-31
PL1633719T3 (pl) 2010-03-31
IL172630A (en) 2011-10-31
RS20050930A (sr) 2008-04-04
AU2004281257C1 (en) 2010-07-01
ATE444953T1 (de) 2009-10-15
IL172630A0 (en) 2006-04-10

Similar Documents

Publication Publication Date Title
BRPI0605921B8 (pt) compostos orgânicos, seus métodos de preparo e uso, bem como composições farmacêuticas
TW200700406A (en) Novel thiophene derivatives
TW200716591A (en) Novel thiophene derivatives
DK1620437T3 (da) 5,7-diaminopyrazolo-4,3-d-pyrimidiner, der er anvendelige til behandling af hypertension
LTPA2013005I1 (lt) Enantiomerų atžvilgiu gryni aminoheteroarilo junginiai, kaip proteinkinazės inhibitoriai
ATE430747T1 (de) 2-pyrimidinyl-pyrazolopyridin-erbb- kinaseinhibitoren
PL381247A1 (pl) Skondensowana pochodna heterocykliczna, zawierająca ją kompozycja lecznicza, oraz jej zastosowanie lecznicze
TW200716552A (en) Novel thiophene derivatives
DK1682530T3 (da) Pyrrolsubstituerede indoler som inhibitorer af PAI-1
TW200738670A (en) Novel thiophene derivatives
EA200501928A1 (ru) Пирролодигидроизохинолины как ингибиторы pde10
TW200800967A (en) Benzimidazole thiophene compounds
CL2003002293A1 (es) Compuestos derivados de indazol; su composicion farmaceutica; su uso en el tratamiento de hipertension ocular.
ATE421501T1 (de) 2,7-substituierte 5-amino-4-hydroxy-8-(1h-indol-5-yl)-octanamid derivate als renin inhibitoren zur behandlung von bluthochdruck
DE602004014772D1 (de) Pyrrol-2,5-dithionderivate als modulatoren des liver-x-rezeptors
ATE549024T1 (de) Chinazolin-kaliumkanalhemmer
NL1028193A1 (nl) Farmaceutisch werkzame verbindingen.
CL2004001507A1 (es) Compuestos derivados de espirobenzobenzazepinas sustituidos, inhibidores de receptores de vasopresina; composicion farmaceutica; utiles en el tratamiento de hipertension, disfuncion cardiaca, insuficiencia renal, entre otras.
WO2005032490A3 (en) Cyclic diamines and derivatives as factor xa inhibitors
EA200801414A1 (ru) Кальцилитические соединения
NO20052557D0 (no) Morfolinderivater for bruk som dopamin-agonister i behandling av blant annet seksuell dysfunksjon.
DE602006003094D1 (de) 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydrochinolin-derivate zur behandlung von unfruchtbarkeit
DK1879580T3 (da) 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydroquinolinderivater som lægemidler til behandling af infertilitet
DK1879581T3 (da) 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydroquinolin-derivater som lægemidler til behandling af infertilitet
ITTO20030850A1 (it) Procedimento per la preparazione di 4-ammino-3,5-dicloro-benzotrifloruro.